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ABSTRACT
Objective The authors performed a randomised trial in
very preterm small-for-gestational age (SGA) babies to
determine if prophylaxis with granulocyte-macrophage
colony-stimulating factor (GM-CSF) improves outcomes
(the PROGRAMS trial). Despite increased neutrophil
counts following GM-CSF, the authors reported no
signiﬁcant difference in neonatal sepsis-free survival.
Patients and methods 280 babies born <31 weeks
of gestation and SGA were entered into the trial.
Outcome was determined at 2 years to determine
neurodevelopmental and general health outcomes,
including economic costs.
Results The authors found no signiﬁcant differences in
health outcomes or health and social care costs between
the trial groups. In the GM-CSF arm, 87 of 134 (65%)
babies survived to 2 years without severe disability
compared with 87 of 131 (66%) controls (RR: 1·0, 95%
CI 0·8 to 1·2). Marginally, more children receiving GM-
CSF were reported to have cough (RR 1·7, 95% CI 1·1
to 2·6) and had signs of chronic respiratory disease
(Harrison’s sulcus; RR 2·0, 95% CI 1·0 to 3·9) though
this was not reﬂected in bronchodilator use or need for
hospitalisation for respiratory disease. Overall, the rate of
neurologic abnormality (7%–9%) was similar but mean
overall developmental scores were lower than expected
for gestational age.
Conclusions The administration of GM-CSF to very
preterm SGA babies is not associated with improved or
more adverse outcomes at 2 years of age. The apparent
excess of developmental impairment in the entire
PROGRAMS cohort, without corresponding increase in
neurological abnormality, may represent diffuse brain
injury attributable to intrauterine growth restriction.
INTRODUCTION
Systemic infection remains a major cause of mortal-
ity and morbidity in the newborn period. Of par-
ticular concern is the association between the
inﬂammatory response and later risk of develop-
mental delay and neurocognitive impairment, pos-
sibly mediated by damage to the periventricular
white matter in the perinatal and neonatal periods.1
Interventions aimed at reducing the impact of neo-
natal sepsis may therefore have longer term beneﬁts
in terms of developmental progress, a reduction in
disability and consequent economic beneﬁts.
Granulocyte-macrophage colony stimulating factor
(GM-CSF) has been shown to be an effective treat-
ment in neutropenia-related infections in patients
with cancer after chemotherapy.2 3 Neutropenia is
common in preterm growth-restricted infants who
are at high risk of acquired infection after birth but a
Cochrane review has suggested there was inadequate
evidence for adoption of GM-CSF in neonatal prac-
tice.4 In order to resolve this matter, we undertook
PROGRAMS, a single blind, multicentre, randomised
trial of GM-CSF in very preterm small-for-gestational
age (SGA) babies, to determine whether treatment
resulted in reduced infections, mortality and morbid-
ity in the neonatal period: 280 newborn SGA infants
of 31 weeks gestational age or less were randomly
allocated to GM-CSF or routine treatment within 72
h of birth. Although neutrophil counts were higher
in GM-CSF-treated babies, there was no signiﬁcant
difference in sepsis or sepsis-free survival between
the two treatment arms,5 in accordance with the ﬁnd-
ings of the systematic review.4
As part of the original design of the trial, we
hypothesised that there might be more subtle bene-
ﬁts over and above short-term outcomes and
designed an outcome evaluation at 2 years of age
(adjusted for prematurity) to determine whether
the administration of GM-CSF in the neonatal
period produced differences in survival free of
severe disability. Simultaneously, we undertook an
What is known on this subject:
▸ Neonatal sepsis confers high mortality and
morbidity after very preterm birth
▸ Very preterm small-for-gestational age (SGA)
babies are at high risk of postnatal neutropenia
and sepsis
▸ Postnatal GM-CSF administration increases
neutrophil counts but does not reduce neonatal
sepsis
What this study adds:
▸ At 2 years, prophylactic administration of
GM-CSF does not improve neurodevelopmental
or health outcomes
▸ This cohort of SGA babies had lower
developmental scores than expected for
gestation
▸ A detailed analysis of health and social care
costs through 2 years of age
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economic study to determine the cost beneﬁt of the use of
GM-CSF.
METHODS
Full details of the PROGRAMS trial have been reported earlier.6
Brieﬂy, participants were infants born at a gestational age of
≤31 completed weeks of gestation with birthweight <10th
centile (UK 1990 growth reference). An infant was not eligible
if there was an immediately life-threatening congenital abnor-
mality, or a strong likelihood of early-onset sepsis, indicated by
maternal pyrexia exceeding 38°C on two occasions during
labour. The study intervention, GM-CSF, in a dose of 10 mg/kg
was given subcutaneously daily for ﬁve consecutive days. No
placebo injections were administered to the standard treatment
arm of the study. Two commercial preparations of recombinant
human GM-CSF were used during the study, molgramostim
(Leucomax, Novartis, UK) and sargramostim (Leukine, Berlex,
California, USA) which have equivalent biological potency for
stimulating granulocyte production and function, both in vitro
and in vivo.
TWO-YEAR OUTCOME EVALUATION
Contact was maintained with the families of the surviving chil-
dren following their discharge from hospital. Children were
traced and families contacted by the study coordinator.
Paediatricians trained and validated in the outcome evaluation
methods using a bespoke training course and video rating of
developmental assessment techniques, evaluated each child in a
clinical setting, usually in a hospital clinic room, but occasionally,
at home. The assessment was carried out as close as possible to 2
years of age adjusted for prematurity (target 24 months±2
months) and comprised measures of growth, a formal clinical
and neurological examination, developed and validated for use
in infants born preterm6 and the Bayley Scales of Infant
Development, second edition (BSID-II).7 In addition, parents
completed a questionnaire with health and socioeconomic details
and the Parent Report of Child Abilities (revised; PARCA-r).8 9
Data were recorded on standardised forms and collated centrally.
Detailed feedback from the examination was posted to the
parents to give to their general practitioner and their paediatri-
cian (if their child was still under the care of a paediatrician).
Disability was classiﬁed as deﬁned in ‘Disability and Perinatal
Care’10 but excluding malformation (a trial exclusion) and
growth domains. Domains assessed were motor, vision, hearing,
development and respiratory, renal and gastrointestinal function.
Outcomes were classiﬁed as either severe disability (any one or
more of BSID-II score >3 SD below the mean or severe motor
outcome (with inability to sit independently, use hands for
feeding or control head, or severe hearing or visual impairment,
or no meaningful words or signs; other disabilities (deﬁned as
BSID-2 scores −2 to −3 SD, ambulant cerebral palsy (CP), and
lesser degrees of sensory loss) or no disability (deﬁned as none
of the above and including children with BSID scores of 1–2 SD
below the mean)11 Bayley standardised scores were classiﬁed in
SD bands below −1 SD according to normative data provided
by Bayley.7 Growth was measured using standardised equip-
ment, including the Leicester height measure, standard weighing
scales (Salter, model 918) and a Lass-o tape measure for head
and arm circumference, and referred to UK Child Growth
Foundation Standards12 or WHO standards for mid upper arm
circumference.13
An economic evaluation, conducted from a NHS and per-
sonal social services perspective,14 reported economic outcomes
up to 2 years of age. Trial data collection forms, combined with
economic questionnaires completed by parents at 6-month inter-
vals, provided a proﬁle of all hospital inpatient and outpatient
service use, surgeries performed, investigative tests, medications
and community health and social care resource use. Unit costs
(£, 2007–2008 prices) collected from primary and secondary
sources in accordance with guidelines for costing healthcare ser-
vices as part of economic evaluation15 were attached to each
item of resource use. Cost effectiveness was expressed in two
forms: incremental cost per additional severe disability-free sur-
vivor and incremental cost per additional disability-free survivor.
The non-parametric bootstrap method was used to construct
cost-effectiveness acceptability curves at alternative willingness
to pay thresholds held by decision makers for the outcomes of
interest.16
STATISTICAL METHODS
The sample size for the initial study was based on the short-term
primary outcome, survival without sepsis for 14 days from trial
entry.5
A CONSORT diagram was constructed, showing the ﬂow of
participants through the study.17 Variables were summarised as
number (per cent) or median (25th centile–75th centile) for cat-
egorical or continuous/ranked data, respectively (none of the
continuous variables approached approximate normality). For
analysis of outcomes, RRs were used to quantify the effect of
treatment on categorical variables. Median differences between
treatment groups were calculated for continuous and ranked
data; 95% CIs were calculated to quantify uncertainty about
RRs and median differences.18
All analyses were done on an intention-to-treat basis, that is,
participants were never excluded from analyses on the basis of
the treatment received. The participants lost to follow-up or
withdrawn were few in number and not included in analyses.
STUDY MANAGEMENT
The study was approved by the South Thames Multicentre
Research Ethics Committee and by the site-speciﬁc review boards
of the 26 recruiting centres. Written informed consent was
obtained from parents. Trial conduct was overseen by a steering
committee and independent Data-Monitoring Committee. This
study is registered as an International Standard Randomised
Controlled Trial, number ISRCTN42553489.
RESULTS
Of 280 babies enrolled into the study, 279 completed the study
intervention, 64 babies died and 203 children (94% survivors)
were evaluated at 2 years of age adjusted for prematurity
(ﬁgure 1). Children were assessed at a median age of 27 months
(range: 23–40 months); 64% of each group were seen within
the target time window and the remainder were older at their
assessment.
There were no systematic differences in study-entry character-
istics or outcomes between the 13 infants (ﬁve received
GM-CSF) who were not followed-up compared with those who
were (web table S1). Children who received GM-CSF and con-
trols who were followed-up were well balanced in respect of
study-entry criteria, neonatal characteristics and short-term out-
comes (table 1) and had similar socioeconomic proﬁles to the
control group (web table S2).
Of the 134 children with known outcomes who received
GM-CSF, 84 survived without severe disability compared with
87 of 131 control children (RR 1.0; 95% CI 0.8 to 1.2). The pro-
portion of surviving children without severe disability in the
GM-CSF group was 87 of 101 and 87 of 102 in the control
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group (RR 1.0; 95% CI 0.9 to 1.1); 14 of the GM-CSF group
and 13 of the controls were assessed to have severe disability (RR
1.2; 0.5 to 2·.7) and 24 and 19 respectively with other disabilities
(RR 1.4; 0.7 to 2.7; table 2). Seven children (three non ambu-
lant) in the GM-CSF group had a motor neurologic abnormality
compared with nine controls (six non ambulant). Similar propor-
tions had bilateral spastic CP (three each), dyskinesia (one each),
unilateral spastic CP (one GM-CSF); two children who received
GM-CSF had unclassiﬁable neurologic abnormalities compared
to six controls (one child in the control arm had both bilateral
spastic CP and dyskinesia). Sensory disability was infrequent;
only one child had severe visual impairment (control) and none
had severe hearing impairment, though three GM-CSF and six
control children had no speech or signing at follow-up. There
were no signiﬁcant differences between the two groups in any
outcome categories.
The median BSID-II mental development index (MDI) was
84 (IQR: 72–98) in the GM-CSF group and 87 (72–96) in con-
trols and median psychomotor development indices (PDI) were
85 (73–96) and 88 (77–100), respectively. These differences
were not statistically signiﬁcant. There were similar proportions
in each of the SD bands (table 3). Of those with severe or other
disability, 5 of 12 from the GM-CSF group and 2 of 10 controls
were classiﬁed as such solely on the basis of their developmental
scores.
Parent report of child development using the PARCA-r ques-
tionnaire also showed no differences between groups. Growth
in height and weight was similarly impaired in both groups
(mean weight and height standard deviation scores (SDS)
ranging from −1·6 to −1·8). Mean head circumference SDS was
−2·1 for both groups (table 3).
Respiratory outcomes at 2 years are shown in table 4. Children
who had received GM-CSF were more likely than controls to be
reported to have cough (36% vs 22%), wheeze without infection
(28% vs 20%) and chest deformity (22% vs 11%), predomin-
antly Harrison’s Sulcus indicating chronic respiratory distress
though these differences were of marginal or no statistical
signiﬁcance. Similar frequencies of hospital re-admissions after
discharge home were reported in the two groups.
There were no signiﬁcant differences in health and social care
costs between the two trial arms (table 5). Mean costs during
the 2-year follow-up period were £62 187 in the GM-CSF
group and £66 260 in the control group, generating a mean
cost difference of £4073 that was not statistically signiﬁcant
(p=0.43). GM-CSF is thus, on average, associated with mar-
ginal cost saving, but also marginally poorer outcomes in terms
of survival without severe or other disability (negative incremen-
tal health effects). When the cost and outcomes data are com-
bined within an incremental cost-effectiveness ratio (deﬁned as
incremental cost divided by incremental health effect), the mean
incremental cost-effectiveness ratio appears in the southwest
quadrant of the cost-effectiveness plane (web appendix ﬁgure
A1). The mean incremental cost-effectiveness ratios within the
PROGRAMS trial were £273 955 per additional severe
disability-free survivor and £83 239 per additional disability-free
survivor. In accordance with methodological guidance (NICE
2008), we also estimated the net monetary beneﬁt of GM-CSF.
The actual health beneﬁts produced by GM-CSF were multi-
plied by alternative willingness to pay values for these beneﬁts,
and the net costs were subtracted. This produced a linear scale
where a negative is unambiguously bad (the costs outweigh the
value placed on the health beneﬁts), and larger beneﬁts are
unambiguously better. Using this ‘net-beneﬁt’ approach, we
were able to assess the probability that GM-CSF is cost effective
across alternative willingness to pay thresholds for the health
outcomes of interest. The probability that GM-CSF is cost
effective at 2 years never exceeded 0.79, which is below the
level normally considered by decision makers as convincing evi-
dence for cost effectiveness.16
DISCUSSION
We have carried out the ﬁrst outcome evaluation at 2 years of
age corrected for preterm birth for SGA babies randomly allo-
cated to receive GM-CSF to prevent neonatal sepsis. In the
treatment group, GM-CSF led to a signiﬁcant increase in neu-
trophil count, but as previously reported,5 this did not result in
reduced sepsis or increased survival. For the planned 2-year
outcome evaluation, reported here, no developmental advantage
was evident for the prophylaxis group and rates of disability,
developmental score proﬁles and economic outcomes were very
similar between the two groups, leading to the conclusion that
GM-CSF is ineffective in improving outcomes to discharge or
to 2 years of age.
We achieved a 94% follow-up rate with no systematic bias
among dropouts in terms of original study variables. The high
follow-up rate and well-validated testing environment mean that
this study is unlikely to have missed a signiﬁcant large beneﬁcial
effect despite the compelling reasons for undertaking the trial.
The trial was halted for a period while the formulation of the
GM-CSF was changed following a strategic decision to cease
production by the concerned pharmaceutical ﬁrm, but there was
no evidence of a differential effect between either of the two
preparations of the compound. The outcome measures are
clearly deﬁned and well used in major epidemiological studies
with good face validity.19 20 The Bayley (BSID-II) assessment is
considered a robust measure of developmental progress and has
been widely used in studies of preterm development and the
results of parental report concur.
The PROGRAMS cohort is unique in representing extreme
prematurity as well as SGA status. Reports of effects of fetal
growth restriction on cognitive outcome are inconsistent21 and
Figure 1 Flow diagram of children recruited to PROGRAMS.
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Table 1 PROGRAMS: infant and maternal characteristics at trial entry and short term outcomes for all children followed-up at 2 years age
corrected for prematurity
GM-CSF (n=101) Control (n=102)
n or median % or IQR n or median % or IQR Difference or RR
95% CI for
difference or RR
Characteristics at trial entry
Male, n (%) 46 46% 50 49% 0.9 0.7 to 1.2
Age at recruitment, h, median (IQR) 43 24–60 46 28–63 −4 −10 to 1
Gestational age, weeks, median (IQR) 29 27–30 29 27–30 0.1 −0.3 to 0.7
Birthweight, g, median (IQR) 839 668 to 932 788 630–928 19 −34 to 70
Neutrophil count at trial entry, ×109/l, median (IQR) 2.7 1.3–4.1 2.6 1.3–4.3 0 −0.6 to 0.5
Neutropaenia (<1.1×109/l) at trial entry, n (%) 16/97 16% 18/97 19% 0.9 0.5 to 1.6
Multiple pregnancies, n (%) 27 27% 22 22% 1.2 0.8 to 2.0
Maternal antenatal steroids administered 4 h or
more before delivery, n (%)
80/87 92% 83/88 94% 1.0 0.9 to 1.1
Infants given surfactant within 4 h of birth, n (%) 70/79 89% 76/82 93% 1.0 0.9 to 1.1
Cranial ultrasound findings at trial entry
Normal 76/100 76% 82/97 85%
Minor abnormality 21/100 21% 12/97 12%
Severe abnormality 3/100 3% 3/97 3%
Short-term outcomes
Necrotising enterocolitis (confirmed at surgery or
post mortem)
2 2% 4 4% 0.5 0.1 to 2.7
Sepsis: culture positive to day 28 from trial entry 26 26% 22 22% 1.2 0.7 to 2.0
Sepsis: culture positive and probable to day 28 29 29% 34 33% 0.9 0.6 to 1.3
Cranial ultrasound findings
Normal 62/88 70% 69/85 81%
Minor abnormality 19/84 22% 9/85 11%
Severe abnormality 7/84 8% 7/85 8%
Oxygen dependency at day 28, n (%) 68 67% 57 56% 1.2 1.0 to 1.5
Oxygen dependency at 36 weeks PMA, n (%) 53 52% 44 43% 1.2 0.9 to 1.6
At discharge:
Child exclusively breastfed 11/100 11% 12/100 12% 1·2* 0.5 to 2.8
Child partially breastfed 16/100 16% 19/100 19% 1·3* 0.6 to 2.6
For categorical variables summary measures are number, %, RR and 95% CI.
For continuous variables summary measures are median (IQR), difference (95% CI).
The denominator is the entire population, unless otherwise stated.
*RR ratio estimated by multinomial regression.
GM-CSF, granulocyte-macrophage colony-stimulating factor.
Table 2 Classification of outcome in PROGRAMS at 2 years of age corrected for prematurity
GM-CSF – control
Outcome GM-CSF (n=139) Control (n=141) RR 95% CI
Death 33/134 24% 31/141 22% 1.1 0.7 to 1.7
Survival without severe disability‡ 87/134 65% 87/131 66% 1.0 0.8 to 1.2
Survival without disability‡ 63/134 47% 68/131 52% 0.9 0.7 to 1.2
Overall function in survivors†
Severe disability‡ 14/101 14% 13/100 13% 1.2§ 0.5 to 2.7
Other disability 24/101 24% 19/100 19% 1.4§ 0.7 to 2.7
No disability 63/101 62% 68/100 68% – –
Neurological abnormality 7/101 7% 9/100 9% 0.8 0.3 to 2.0
* Unable to trace or abroad.
†One not done, two assessed by non-study paediatrician but insufficient information to classify disability.
‡Using criteria outlined in references 11 and 12. Malformation and growth domains have been excluded from the disability criteria.
§RR ratio estimated by multinomial logistic regression.
GM-CSF, granulocyte-macrophage colony-stimulating factor.
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there is no reference group for comparison. The proportion of
children with disability and the pattern of clinical features in
this particularly vulnerable group are thus of wider interest. In a
population of extremely preterm babies, one would expect
some depression of cognitive scores22–24 and this is reﬂected in
our ﬁnding of an approximately 1 SD disadvantage in MDI and
PDI scores over the normative population for the children in
the PROGRAMS trial. The median gestational age of the
PROGRAMS cohort was 29–30 weeks. However, their mean
MDI and PDI scores (84–87 and 85–88, respectively) were of
an equivalent level to those of an epidemiological cohort of
babies born at a much greater degree of immaturity, 25 weeks
or less, (the EPICure cohort; 84 and 87, respectively)19 and
considerably lower than those of a contemporary population of
babies born at 31 weeks or less gestational age and enrolled
into a randomised trial of parental intervention (the PIP Study:
91–93 and 92–95, respectively).25 In contrast, the rate of neuro-
logic abnormality was, as expected, lower in the PROGRAMS
group (7%–9%) compared with the EPICure cohort (24%).19
The same team trained assessors for the PROGRAMS, EPICure
and PIP studies and developmental assessment techniques were
similar. We therefore speculate that the apparent excess in devel-
opment impairment seen in the entire PROGRAMS cohort may
reﬂect the vulnerability to global brain injury and developmental
delay attributable to fetal growth restriction.
We might have anticipated improvement in neurodevelop-
ment on several counts. First that neonatal sepsis is itself asso-
ciated with worsened neurodevelopmental outcomes.26 27
Modulation of inﬂammatory mechanisms by GM-CSF might
have improved outcomes, not evident during the neonatal
period, through subtle alteration of the responses to infection.
There is evidence that GM-CSF may be neuroprotective.
GM-CSF crosses the blood–brain barrier and counteracts pro-
grammed cell death, and in experimental models of stroke was
found to decrease damage.28
The only signiﬁcant difference between the trial groups
was the marginally worse respiratory outcomes for the
GM-CSF-treated group in terms of recurrent cough and chest
deformity. This contrasts with worse short-term markers of neo-
natal lung disease in the control group. Twenty-three children in
Table 3 Developmental and growth outcomes in children recruited to PROGRAMS at 2 years of age corrected for prematurity. The denominator
indicates the number of children for whom parents returned questionnaires or who completed the Bayley Assessment
GM-CSF Control GM-CSF – control
Outcome Med (IQR) or n% Med (IQR) or n%
Median difference
(95% CI)
Bayley scales of infant development
Mental development index n=90 n=89
Median (IQR) scores 84 (72–98) 87 (72–96) 0 (−4 to 5)
Score <55 12 13% 10 11%
Score 55–69 7 8% 6 7%
Score 70–84 28 31% 27 30%
Score >84 43 48% 46 52%
Psychomotor development index n=88 n=90
Median (IQR) scores 85 (73–96) 88 (77–100) −3 (−8 to 1)
Score <55 9 10% 11 12%
Score 55–69 11 13% 4 4%
Score 70–84 24 27% 19 21%
Score >84 44 50% 56 62%
PARCA-r (parent report of child development) (n=75) (n=76)
Development 26 22–29 26 23–29 0 −1 to 2
Vocabulary 46 25–68 38 16–68 7 −3 to 17
Sentence complexity 0 0–3 0 0–2 0 0 to 0
Parent report composite 73 50–100 65 41–102 7 −5 to 19
Parent report composite <49‡ 17 24% 25 34% 0.7 0·4 to 1·2
Growth Mean (SD) Mean (SD) Difference in means (95% CI)
Height Cm 85 (5) 84 (4)
SDS* −1.6 (1.4) −1.7 (1.1) 0.1 (−0.3 to 0.5)
Weight Kg 11 (1.8) 11 (1.3)
SDS −1.7 (1.4) −1.8 (1.2) 0.0 (−0.3 to 0.4)
Head circumference Cm 48 (1.9) 47 (1.8)
SDS −2.1 (1.5) −2.1 (1.4) 0.1 (−0.3 to 0.5)
Midupper arm circumference Cm 15 (1.5) 15 (1.2)
SDS† −0.6 (0·8) −0.8 (0.7) 0.1 (−0.1 to 0.4)
Abdominal circumference Cm 47 (5.3) 46 (3.2) 0.85 (−0.5 to 2.2)
*Height, weight, head circumference standard deviation scores (SDS) scores from child growth foundation standards.
†Midupper arm circumference standard deviation scores from WHO Expert committee.
‡Parental questionnaire composite of non-verbal development, sentence complexity and vocabulary. Forty nine is the cut off for cognitive delay equivalent to bayley mental development
index ≤70.
GM-CSF, granulocyte-macrophage colony-stimulating factor.
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the control arm were discharged home with supplemental
oxygen compared with 16 in the GM-CSF arm. Babies who are
born following fetal growth restriction appear to be at high risk
for chronic respiratory disease or bronchopulmonary dyspla-
sia.29–31 This is supported by our ﬁnding that 40% of the trial
population were receiving supplemental oxygen at 36 weeks
postmenstrual age.6 Cough and wheeze were marginally more
common in the GM-CSF group and more children had chest
deformity. However, the implication that ongoing respiratory
symptoms are more frequent in the GM-CSF arm of the
trial was not reﬂected in the use of bronchodilators or in any
excess need for hospital readmission for respiratory disease.
Table 5 Mean health and social care costs over the first 2 years of life and mean cost differences between trial groups by cost category (UK £
sterling, 2007–2008 prices)
GM-CSF (n=134) Control (n=131)
Cost category Mean (SE) Mean (SE) Mean difference (95% CI)*
Neonatal care 50 464 (2837) 56339 (3345) −5875 (−14 369 to 2620)
Follow-up care (to 6 months) 5321 (690) 3771 (447) 1550 (−43 to 3143)
Follow-up care (6–12 months) 2698 (478) 2349 (398) 349 (−863 to 1561)
Follow-up care (12–18 months) 1948 (312) 1837 (321) 112 (−772 to 995)
Follow-up care (18–24 months) 1753 (264) 1963 (372) −209 (−1104 to 686)
Total health and social care 62 186 (3517) 66 260 (3775) −4073 (−14 239 to 6093)
*Bootstrap estimation using 10 000 replications, bias corrected.
GM-CSF, granulocyte-macrophage colony-stimulating factor.
Table 4 PROGRAMS: respiratory and hospital readmission outcomes from discharge from inpatient neonatal
care through to 2 years of age corrected for prematurity. The denominator indicates the number of children for
whom questionnaires were returned
GM-CSF
(n−=−100) Control (n=101)
Outcome n/total (%) n/total (%) RR 95% CI
Chest symptoms
Cough
>once a week 10 (10) 16 (16)
Weekly–monthly 12 (12) 0 (0)
Once a month or less 30 (30) 30 (30)
Cough without infection 36 (36) 22 (22) 1·7 (1·1 to 2·6)
Wheeze
>once a week 5 (5) 6 (6)
Weekly–monthly 5 (5) 5 (5)
Once a month or less 22 (22) 19 (19)
Wheeze without infection 28 (28) 20 (20) 1·4 (0·9 to 2·3)
Chest medicines
Bronchodilators during last 12 months 22 (22) 26 (26) 0·9 (0·5 to 1·4)
Inhaled steroids during last 12 months 12 (12) 10 (10) 1·2 (0·5 to 2·8)
Supplemental oxygen at discharge 16/98 (16) 23 (23) 0·7 (0·4 to 1·3)
Supplemental oxygen at 2 years 1 (1) 2 (2) 0·5 (0·0 to 5·5)
Respiratory examination
Tracheostomy 0/95 (0) 1/98 (1) –
Chest deformity 20/92 (22) 10/90 (11) 2·0 (1·0 to 3·9)
Harrison’s sulcus 19/92 (21) 10/90 (11)
Hyperinflation 9/92 (10) 1/90 (1)
Hospital admissions
Respiratory admission (n) 35 (35) 37 (37) 1·0 (0·7 to 1·4)
Median no. (upper quartile; max)* 2 (3; 8) 1 (2; 4)
Surgical admission (n) 18 (19) 22 (22) 0·8 (0·5 to 1·5)
Median no. (upper quartile; max)* 1 (1; 2) 1 (2; 4)
ICU admission and ventilated (n) 3 (3) 5 (5) 0·6 (0·2 to 2·5)
Median no. (upper quartile; max)* 1 (1; 1) 1 (1·5; 2)
Admission other reason (n) 10/55 (18) 8/59 (14) 1·3 (0·6 to 3·1)
Median no. (upper quartile; max)* 1 (1; 2) 1 (2; 4)
*Median number of admissions among those who had an admission.
GM-CSF, granulocyte-macrophage colony-stimulating factor; ICU, intensive care unit.
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Respiratory signs were not prespeciﬁed trial outcomes and the
differences may have arisen by chance.
On theoretical grounds, GM-CSF might inﬂuence respiratory
function in two opposing ways. Acute activation of neutrophils
and monocytes in the lungs at the time of administration might
lead to lung damage, though this has not been observed in
extensive adult clinical practice. Conversely, GM-CSF has been
postulated to be protective, though when this effect was tested
in adults with acute lung injury through a randomised trial,
GM-CSF treatment led to no difference in ventilator days or
mortality.32 In the PROGRAMS cohort, an increase in immedi-
ate or long-term oxygen requirement was not seen in babies
receiving GM-CSF in this or our previous study.4 5 The second
is the inﬂuence of GM-CSF on the balance between TH1
and TH2 immune responses. The newborn immune system is
TH1 deﬁcient, hence less effective at mounting antibacterial
responses.33 GM-CSF is a TH1 agonist and might be expected
to accelerate the switch away from TH2 dominance that in turn
might plausibly translate into a reduction in later asthma.34 To
our best knowledge, this has never been investigated in a clinical
study. This will be of great interest as we continue monitoring
respiratory outcomes at 5-year follow-up.
CONCLUSIONS
The administration of GM-CSF to very preterm SGA babies is
not associated with improved or more adverse developmental or
health outcomes at 2 years of age. The apparent excess of devel-
opmental impairment in the PROGRAMS cohort, without cor-
responding increase in neurological abnormality, may represent
diffuse brain injury attributable to intrauterine growth restric-
tion. The stability of diagnoses between 2-year assessments and
childhood measures of cognitive performance has been ques-
tioned recently.35 36 Developmental scores may vary widely in
individuals even if the proportions within each group remain
roughly the same in a preterm population. It is therefore
important to evaluate more subtle and predictive outcomes at
school age before the hypothesis that GM-CSF has no beneﬁt in
this very high-risk population can be rejected.
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